Stock Report

All about this stock under one free report Last Updated: 09-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Asston Pharmaceuticals Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 544445

₹110.00

up-down-arrow ₹-4.60 (-4.01%)

As on 08-Sep-2026IST

Market cap

info icon

₹120 Cr

Revenue (TTM)

info icon

₹25 Cr

P/E Ratio

info icon

31.1

P/B Ratio

info icon

1.8

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- 60.65 37.66 --
EBIT -- -- 143.60 165.47 --
Net Profit -- -- 217.95 239.43 --
EPS -- -- 217.94 226.85 --
Book Value -- -- 67.66 117.56 --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsMar-25Mar-24Mar-23
EBIT-Margin info 20.97--24.2816.0122.63
Net Margin info 13.39--16.898.5914.69
Return on equity info 51.84--50.5632.4772.49
Return on Capital info 35.58--42.6426.9037.20
Return on Assets info 11.67--17.898.019.11
Debt to Equity (x) info ----0.681.072.64

Profitability

View Detailed Peer Comparison

ROCE

42.64

Higher than Peers by 26.19

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
42.64
26.90
37.20
13.97
--
Peer Median
16.46
15.49
17.37
17.62
--
ROE

50.56

Higher than Peers by 36.68

Profit after tax / Average Net worth * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
50.56
32.47
72.49
11.90
--
Peer Median
13.87
14.72
15.70
18.36
--
ROA

17.89

Higher than Peers by 9.85

Profit after tax / Average Total assets * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
17.89
8.01
9.11
1.17
--
Peer Median
8.04
7.19
9.43
9.43
--
EBIT Margin

24.28

Higher than Peers by 14.23

Operating profit (EBIT) / Net Sales * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
24.28
16.01
22.63
-3.79
--
Peer Median
10.05
10.28
13.90
17.27
--
Net Margin

16.89

Higher than Peers by 7.78

Net profit / Total Income (Net sales plus other income) * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
16.89
8.59
14.69
1.05
--
Peer Median
9.11
6.78
10.91
12.99
--
Cash Profit Margin

17.60

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
17.60
9.05
16.73
1.24
--
Peer Median
--
--
--
--
--

Growth

View Detailed Peer Comparison

Revenue Growth

60.65

Higher than Peers by 53.48

Year on year growth in net sales

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
60.65
138.39
-31.89
--
--
Peer Median
7.17
10.56
12.63
15.47
--
EBIT Growth

143.60

Higher than Peers by 131.55

Year on year growth in operating profit (EBIT)

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
143.60
68.64
506.71
--
--
Peer Median
12.05
6.17
-2.90
51.73
--
Net Profit Growth

217.95

Higher than Peers by 195.80

Year on year growth in profit after tax

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
217.95
28.74
855.33
--
--
Peer Median
22.15
27.97
-14.10
44.15
--
EPS Growth

217.94

Higher than Peers by 209.14

Year on year growth in earnings per share

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
217.94
14.96
855.34
--
--
Peer Median
8.80
--
-3.68
38.52
--
Book Value Growth

67.66

--

Year on year growth in book value per share

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
67.66
221.89
113.70
--
--
Peer Median
--
--
--
--
--

Solvency

View Detailed Peer Comparison

Debt to Equity

0.68

Higher than Peers by 0.64

Total debt / Net worth

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
0.68
1.07
2.64
3.56
--
Peer Median
0.03
0.05
0.14
0.23
--
Short term debt to equity ratio

0.35

--

(Short term borrowings / Net worth)

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
0.35
0.71
1.58
2.49
--
Peer Median
--
--
--
--
--
Current Ratio

1.80

Lower than Peers by 0.40

Current Assets / Current Liabilities and Provisions

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
1.80
1.52
1.09
0.98
--
Peer Median
2.20
1.93
1.82
1.75
--
Quick Ratio

1.75

Higher than Peers by 0.04

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
1.75
1.40
0.94
0.91
--
Peer Median
1.72
1.59
1.30
1.04
--
Interest Coverage

7.00

Lower than Peers by 5.28

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
7.00
2.95
2.96
1.37
--
Peer Median
12.28
12.45
16.98
15.07
--

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

98.04

Higher than Peers by 71.81

Debtors outstanding / Net Sales * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
98.04
103.63
131.67
66.71
--
Peer Median
26.23
23.97
24.57
20.26
--
Asset Turnover

1.04

Higher than Peers by 0.30

Sales / Average Total Assets

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
1.04
0.92
0.56
1.01
--
Peer Median
0.74
0.88
0.82
0.79
--
Receivable days

296.65

--

Average Debtors / Sales * 365

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
296.65
289.92
419.04
243.49
--
Peer Median
--
--
--
--
--
Inventory Days

15.72

--

Average Inventory / Sales * 365

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
15.72
34.42
55.94
19.14
--
Peer Median
--
--
--
--
--
Payable days

190.57

--

Average Creditors / Cost of goods sold * 365

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
190.57
250.27
685.40
246.66
--
Peer Median
--
--
--
--
--
Cash Conversion Cycle

121.80

--

Receivable Days + Inventory Days - Payable Days

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
121.80
74.08
-210.43
15.97
--
Peer Median
--
--
--
--
--

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
--
--
--
--
--
Peer Median
39.17
40.74
25.97
33.71
--
Price / Book Value

--

--

Current share price divided by book value per share in the latest financial year

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
--
--
--
--
--
Peer Median
3.61
3.87
2.79
4.36
--
EV/EBITDA

1.98

Lower than Peers by 26.81

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
1.98
2.71
2.68
6.45
--
Peer Median
28.79
25.41
15.07
23.32
--
Market Cap

--

--

Current Share price multiplied by latest total number of shares outstanding

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Asston Pharmaceuticals
--
--
--
--
--
Peer Median
3,944
2,959
3,742
6,050
--
loading...
loading...
loading...